Mussallem Michael A's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 11, 2023
- Accession no.
- 0001225208-23-005754
- Filed
- May 11, 2023
- Trade date
- May 7-10, 2023
- Filing delay
- 4 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.76M. It was filed 4 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mussallem Michael ACIK 0001204551 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2023 | Common Stock | MOption exerciseAcquired | +20,777 | $0.00F1 | $0 | 81,724.82 | Direct | |
| May 10, 2023 | Common Stock | MOption exerciseAcquired | +29,375 | $35.20 | +$1,034,000 | 111,099.82 | Direct | |
| May 10, 2023 | Common Stock | SSaleDisposed | −5,984 | $88.94F3 | −$532,216.96 | 105,115.82 | Direct | |
| May 10, 2023 | Common Stock | GGiftDisposed | −9,500 | $0.00 | $0 | 95,615.82 | Direct | |
| May 10, 2023 | Common Stock | SSaleDisposed | −13,891 | $88.29F4 | −$1,226,436.39 | 81,724.82 | Direct | |
| May 10, 2023 | Common Stock | GGiftAcquired | +9,500 | $0.00 | $0 | 3,616,922 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2023 | Common Stock | MOption exerciseDisposed | −20,777 | $0.00 | $0 | 5,698 | Direct | |
| May 10, 2023 | Common Stock | MOption exerciseDisposed | −29,375 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $88.84 to $89.25 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $87.83 to $88.83 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.